CoagulationDisorders near Staten Island, NY

Biography: Nausheen Hakim, DO, is a hematologist and oncologist at NewYork-Presbyterian Medical Group Queens, affiliated with NewYork-Presbyterian Queens Hospital. She is an assistant professor of clinical medicine at Weill Cornell Medicine. Dr. Hakim has a special interest in the area of genitourinary cancers. Active in research, Dr. Hakim has published in several medical journals, as well as delivered presentations at the American Society of Clinical Oncology and the World Lung Conference. After obtaining her bachelor of arts in anthropology while pursuing the pre-medicine track, she volunteered for one year with AmeriCorps at the nonprofit South Asian Youth Action (SAYA). She graduated from New York College of Osteopathic Medicine and completed her internal medicine residency at Drexel University/Hahnemann Hospital in Philadelphia. She served her hematology and medical oncology fellowship at the Northwell Health Cancer Institute. Dr. Hakim remains dedicated to the world of nonprofit by participating on the advisory board of Unite for Health. With a commitment to working in global health, she strives to better understand palliative care barriers in not only communities abroad, but in our own communities here in Queens.

Biography: Dr. Amengual is the Herbert Irving Associate Professor of Medicine in the Division of Hematology and Oncology, Center for Lymphoid Malignancies, and Hebert Irving Comprehensive Cancer Center here at Columbia University Irving Medical Center. Dr. Amengual obtained a degree in Nutritional Sciences at Cornell University where she graduated with honors. She attained her Medical Doctorate from New York Medical College, followed by a residency in Internal Medicine at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Amengual then went on to complete her fellowship in Hematology and Oncology at the NYU Langone Medical Center, where she participated in the Physician-Scientist Training Program and graduated as a Dean's Scholar. She is the recipient of several awards and scholarships for her research, including the Irving Scholarship, the Gabrielle's Angel Foundation for Cancer Research and as a Scholar of the Amos Medical Faculty Development Award Robert Wood Johnson Foundation and the American Society of Hematology. She was also selected to participate in the prestigious American Association for Cancer Research (AACR)/American Society of Clinical Oncology (ASCO) Vail Workshop Methods in Clinical Cancer Research, the European Hematology Association/American Society of Hematology Translational Research Training Program and the South West Oncology Group (SWOG) Leadership Academy. These competitive programs select the most promising faculty for enriched development and have laid the foundation for her research. She has now served on the faculty or review committee of several of these programs. As an R01-funded physician-scientist, Dr. Amengual is focused on translating the latest scientific discoveries regarding cancer cell behavior into novel treatment platforms. She aims to translate observations and concepts developed in the laboratory directly into patient care. Specifically, she is focused on combination epigenetic targeting for both B-cell and T-cell lymphomas. She continues to develop new pharmacologic strategies directed at altering these diseases at their genetic roots, now collaborating with investigators from backgrounds of diverse scientific expertise. Dr. Amengual has been studying the effects HDAC inhibitors in combination with EZH2 inhibitors to capitalize on two common mutations driving growth of diffuse large B-cell lymphoma cells. In addition, she has studied targeting the BCL6:p53 pathway in order to shift the balance of oncogene and tumor suppressor function using novel therapeutic approaches. For T-cell lymphoma Dr. Amengual has led a clinical trial combining HDAC inhibitors with the novel antifolate drug, pralatrexate. The pralatrexate plus romidepsin combination has led to dramatic responses in patients with relapsed T-cell lymphoma and will serve as the basis of more trials to come aimed at improving outcomes with patients with these diseases. Building on these discoveries, Dr. Amengual is now evaluating the interplay of epigenetics with immune surveillance and endogenous retroviral expression in the setting of lymphoma. Dr. Amengual has lectured at academic institutions and conferences around the world, and at forums such as the Lymphoma Research Foundation and the American Hematology Society's Highlights of ASH. She has published numerous chapters and peer reviewed articles on the biology and treatment of lymphoma, and serves as a Scientific Reviewer for a number of journals in the field, including Journal of Clinical Oncology and as an Editorial Board Member of Clinical Cancer Research. She has sat on grant review and abstract review committees for meetings such as the American Society of Hematology where she has also chaired sessions, American Society of Clinical Oncology and the Doris Duke Charitable Foundation. She is actively involved in the NCI's National Clinical Trial Network, SWOG, as a Lymphoma Working Group Committee Member. Dr. Amengual is involved in numerous clinical trials for lymphoma, enabling our patients to access the best opportunities for the treatment of their disease. Dr. Amengual has clinical expertise in lymphoma, HIV- and EBV-related hematologic illnesses.

Biography: Dr. Natalie Porat, MD is a Maternal-Fetal Medicine Specialist who practices in Newark, NJ. She is 40 years old and has been practicing for 14 years. Dr. Natalie Porat, MD is affiliated with Newark Beth Israel Medical Center.

Care Philosophy: Where Care and Compassion Matters

Biography: Dr. Erin Mulvey is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. She is also an assistant attending physician at NewYork-Presbyterian Queens, She completed her undergraduate education at Boston University where she earned a degree in Biochemistry and Molecular Biology. She received her medical degree from New York Medical College. Dr. Mulvey completed both her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital and Weill Cornell Medical College.